Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.77 0.06 −0.77%
Market cap
$451.7M
P/E
20.4×
Fwd P/E
0.0×
Dividend yield
5.41%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
19.32 23.83 20.17 19.28

+8 more quarters

P/S ratio
2.21 2.71 2.26 2.34
P/FCF ratio
16.15 30.09 26.00 22.27
P/Operating CF
23.52 (1,691.74) 53.79 39.21
P/B ratio
1.58 1.90 1.51 1.54
EV/Sales
1.94 2.42 1.95 2.05
EV/EBITDA
8.61 10.86 8.56 8.32
EV/FCF
14.12 26.93 22.50 19.51
Current Ratio
4.06 3.33 4.07 4.03
Net Debt/EBITDA
(4.78) (5.79) (8.92) (5.31)
Debt/Equity
0.02 0.04 0.04 0.04
Earnings Yield
5.18% 4.20% 4.96% 5.19%
Free Cash Flow Yield
6.19% 3.32% 3.85% 4.49%
Free Cash Flow per Share
0.28 (0.02) 0.08 0.12
Book value per Share
4.66 4.39 4.67 4.51
Free Cash Flow
15.96 (1.26) 4.79 6.83
EV/EBIT
13.35 17.35 13.42 12.89
Other line items

Show all line items

Columns are period end dates